Skip to content

COVID-19 Primary care Platform for Early treatment and Recovery (COPPER) Study: an open-label randomized controlled trial

COVID-19 Primary care Platform for Early treatment and Recovery (COPPER) Study: an open-label randomized controlled trial - COPPER

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON50987
Enrollment
2000
Registered
2021-01-28
Start date
2021-02-16
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corona COVID-19

Interventions

6 mg dexamethasone prescribed during ten days and as a precaution combined with electronic monitoring of saturation and other signs and symptoms

Sponsors

General Practitioners Research Institute
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age *18 years - A positive test for SARS-CoV-2 - A GP consultation for deteriorating COVID-19 symptoms - Exercise-induced desaturation, defined as a drop of *4% in SpO2 and/or to

Exclusion criteria

Exclusion criteria: - Inability to understand and sign the written consent form - Inability to perform saturation measurements or sit-to-stand test - Not willing to be admitted to hospital - On the discretion of the recruiting clinician if he or she deems a patient not eligible - Contra-indication for dexamethasone - History of gastrointestinal bleeding

Design outcomes

Primary

MeasureTime frame
The primary outcome will be time to first hospital admission.

Secondary

MeasureTime frame
Secondary outcomes are time to self-reported recovery, COVID-19 severity and self-reported disease burden.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)